In 2019, the European Crohn’s and Colitis Organisation released guidelines for the medical management of Crohn’s disease, concerning the induction of remission, the maintenance of remission and the treatment of fistulising perianal disease. This review summarises the key recommendations regarding the use of biologics in these settings.
- Crohn's disease
Statistics from Altmetric.com
Contributors DS, JPS and MG came up with the concept, drafted the manuscript and contributed equally. All authors agreed to the final version of the manuscript.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests MG has served on the advisory board of Pfizer and Pharmacosmos and has received speaker fees, research or travel grants from Abbvie, Celltrion, Janssen, Pfizer, Pharmacosmos, Takeda and Vifor. JPS has received speaker fees for Janssen, Abbvie and Takeda.
Provenance and peer review Not commissioned; internally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.